RSS-Feed abonnieren
DOI: 10.1055/s-2005-922050
© Georg Thieme Verlag Stuttgart · New York
Isolierte systolische Hypertonie
Isolated systolic hypertensionPublikationsverlauf
eingereicht: 27.7.2005
akzeptiert: 5.10.2005
Publikationsdatum:
10. November 2005 (online)

In den letzten Jahren zeigt sich zunehmend im praktischen Alltag eine Form der Hypertonie, die sich durch deutlich erhöhten systolischen Blutdruck bei normalem diastolischem Blutdruck äußert. Patienten klagen bei dieser Art des Hochdrucks immer wieder über sehr stark schwankende und zum Teil medikamentös nur schwer einstellbare Blutdruckwerte. Sowohl Patienten wie auch die behandelnde Ärzte verzweifeln nicht selten an dieser Blutdruckkonstellation. Nach den WHO Guidelines und auch den Empfehlungen der deutschen und europäischen Hochdruckgesellschaften wird ein erhöhter systolischer Blutdruck über 140 mmHg bei gleichzeitig normalen diastolischen Blutdruck unter 90 mmHg als isolierte systolische Hypertonie (ISH) bezeichnet. Typisches Charakteristikum ist der erhöhte Pulsdruck, der sich aus der Differenz von systolischem und diastolischen Blutdruck errechnen lässt. Sowohl die isolierte systolische Hypertonie wie aber auch der erhöhte Pulsdruck sind unabhängige Risikofaktoren für kardiovaskuläre Folgeerkrankungen.
kurzgefasst: Eine isolierte systolische Hypertonie liegt vor, wenn der systolische Blutdruck über 140 mmHg liegt und der diastolische Blutdruck unter 90 mmHg bleibt. Eine typische Begleiterscheinung ist der erhöhte Pulsdruck, der sich aus der Differenz von systolischem und diastolischen Blutdruck berechnen lässt. Beides sind unabhängige kardiovaskuläre Risikofaktoren.
Literatur
- 1
The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group .
Rationale and design of a randomized clinical trial on prevention of stroke in isolated
systolic hypertension.
J Clin Epidemiol.
1988;
41
1197-1208
MissingFormLabel
- 2
SHEP Cooperative Research Group .
Prevention of stroke by antihypertensive drug treatment in older persons with isolated
systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program
(SHEP).
Jama.
1991;
265
3255-3264
MissingFormLabel
- 3
Arking D E, Atzmon G, Arking A, Barzilai N, Dietz H C.
Association between the functional variant of KLOTHO allele and high-density lipoprotein
cholesterol, blood pressure, stroke, and longevity.
Circ Res.
2005;
96
412-418
MissingFormLabel
- 4
Asmar R, Gosse P, Topouchian J, N’Tela G, Dudley A, Shepherd G L.
Effects of telmisartan on arterial stiffness in Type 2 diabetes patients with essential
hypertension.
J Renin Angiotensin Aldosterone Syst.
2002;
3
176-180
MissingFormLabel
- 5
Asmar R, Hugues C, Pannier B, Daou J, Safar M E.
Duration of action of bisoprolol after cessation of a 4 week treatment and its influence
on pulse wave velocity and aortic diameter: a pilot study in hypertensive patients.
Eur Heart J.
1987;
8
(Suppl M)
115-120
MissingFormLabel
- 6
Asmar R G, London G M, O’Rourke M E, Safar M E.
Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose
perindopril/indapamide combination in hypertensive patient: a comparison with atenolol.
Hypertension.
2001;
38
922-926
MissingFormLabel
- 7
Bailey M, Pillarisetti S, Jones P, Xiao H, Simionescu D, Vyavahare N.
Involvement of matrix metalloproteinases and tenascin-C in elastin calcification.
Cardiovasc Pathol.
2004;
13
146-155
MissingFormLabel
- 8
Benetos A et al.
Determinants of accelerated progression of arterial stiffness in normotensive subjects
and in treated hypertensive subjects over a 6-year period.
Circulation.
2002;
105
1202-1207
MissingFormLabel
- 9
Benetos A, Vasmant D, Thiery P, Safar M.
Effects of ramipril on arterial hemodynamics.
J Cardiovasc Pharmacol.
1991;
18
S153-156
(Suppl 2)
MissingFormLabel
- 10
Blacher J, Raison J, Amah G, Schiemann A L, Stimpel M, Safar M E.
Increased arterial distensibility in postmenopausal hypertensive women with and without
hormone replacement therapy after acute administration of the ACE inhibitor moexipril.
Cardiovasc Drugs Ther.
1998;
12
409-414
MissingFormLabel
- 11
Blacher J, Staessen J A, Girerd X, Gasowski J, Thijs L, Liu L, Wang J G, Fagard R H, Safar M E.
Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive
patients.
Arch Intern Med.
2000;
160
1085-1089
MissingFormLabel
- 12
Bortolotto L A, Safar M E, Billaud E, Lacroix C, Asmar R, London G M, Blacher J.
Plasma homocysteine, aortic stiffness, and renal function in hypertensive patients.
Hypertension.
1999;
34
837-842
MissingFormLabel
- 13
Burt V L, Cutler J A, Higgins M, Horan M J, Labarthe D, Whelton P, Brown C, Roccella E J.
Trends in the prevalence, awareness, treatment, and control of hypertension in the
adult US population. Data from the health examination surveys, 1960 to 1991.
Hypertension.
1995;
26
60-69
MissingFormLabel
- 14
Burt V L, Whelton P, Roccella E J, Brown C, Cutler J A, Higgins M, Horan M J, Labarthe D.
Prevalence of hypertension in the US adult population. Results from the Third National
Health and Nutrition Examination Survey, 1988 - 1991.
Hypertension.
1995;
25
305-313
MissingFormLabel
- 15
Chae C U, Pfeffer M A, Glynn R J, Mitchell G F, Taylor J O, Hennekens C H.
Increased pulse pressure and risk of heart failure in the elderly.
Jama.
1999;
281
634-639
MissingFormLabel
- 16
Domanski M J, Davis B R, Pfeffer M A, Kastantin M, Mitchell G F.
Isolated systolic hypertension: prognostic information provided by pulse pressure.
Hypertension.
1999;
34
375-380
MissingFormLabel
- 17
Ferrier K E, Muhlmann M H, Baguet J P, Cameron J D, Jennings G L, Dart A M, Kingwell B A.
Intensive cholesterol reduction lowers blood pressure and large artery stiffness in
isolated systolic hypertension.
J Am Coll Cardiol.
2002;
39
1020-1025
MissingFormLabel
- 18
Franklin S S, Gustin W t, Wong N D, Larson M G, Weber M A, Kannel W B, Levy D.
Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart
Study.
Circulation.
1997;
96
308-315
MissingFormLabel
- 19
Franklin S S, Khan S A, Wong N D, Larson M G, Levy D.
Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham
heart study.
Circulation.
1999;
100
354-360
MissingFormLabel
- 20
Izzo J L, Shykoff B E.
Arterial stiffness: clinical relevance, measurement, and treatment.
Rev Cardiovasc Med.
2001;
2
29-34, 37 - 40
MissingFormLabel
- 21
Kannel W B, Gordon T, Schwartz M J.
Systolic versus diastolic blood pressure and risk of coronary heart disease. The Framingham
study.
Am J Cardiol.
1971;
27
335-346
MissingFormLabel
- 22
Kass D A, Shapiro E P, Kawaguchi M, Capriotti A R, Scuteri A, deGroof R C, Lakatta E G.
Improved arterial compliance by a novel advanced glycation end-product crosslink breaker.
Circulation.
2001;
104
1464-1470
MissingFormLabel
- 23
Komai N, Ohishi M, Moriguchi A. et al .
Low-dose doxazosin improved aortic stiffness and endothelial dysfunction as measured
by noninvasive evaluation.
Hypertens Res.
2002;
25
5-10
MissingFormLabel
- 24
Kostis J B, Lawrence-Nelson J, Ranjan R, Wilson A C, Kostis W J, Lacy C R.
Association of increased pulse pressure with the development of heart failure in SHEP.
Systolic Hypertension in the Elderly (SHEP) Cooperative Research Group.
Am J Hypertens.
2001;
14
798-803
MissingFormLabel
- 25
Kuro-o M, Matsumura Y. et al .
Mutation of the mouse klotho gene leads to a syndrome resembling ageing.
Nature.
1997;
390
45-51
MissingFormLabel
- 26
Lehmann E D.
Terminology for the definition of arterial elastic properties.
Pathol Biol (Paris).
1999;
47
656-664
MissingFormLabel
- 27
Lichtenstein M J, Shipley M J, Rose G.
Systolic and diastolic blood pressures as predictors of coronary heart disease mortality
in the Whitehall study.
Br Med J (Clin Res Ed).
1985;
291
243-245
MissingFormLabel
- 28
Liu L, Wang J G, Gong L, Liu G, Staessen J A.
Comparison of active treatment and placebo in older Chinese patients with isolated
systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group.
J Hypertens.
1998;
16
1823-1829
MissingFormLabel
- 29
McEniery C M, Wallace S, Dakham Z, Pusalkar P, Ashby M J, Cockcroft J R, Wilkinson I B.
Matrix Metalloproteinase-9 (MMP-9), MMP-2, and Serum Elastase Activity Are Associated
With Systolic Hypertension and Arterial Stiffness.
Arterioscler Thromb Vasc Biol.
2005;
25
372-378
MissingFormLabel
- 30
Mitchell G F, Parise H, Benjamin E J, Larson M G, Keyes M J, Vita J A, Vasan R S, Levy D.
Changes in arterial stiffness and wave reflection with advancing age in healthy men
and women: the Framingham Heart Study.
Hypertension.
2004;
43
1239-1245
MissingFormLabel
- 31
Morgan T, Lauri J, Bertram D, Anderson A.
Effect of different antihypertensive drug classes on central aortic pressure.
Am J Hypertens.
2004;
17
118-123
MissingFormLabel
- 32
Neaton J D, Blackburn H. et al .
Serum cholesterol level and mortality findings for men screened in the Multiple Risk
Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group.
Arch Intern Med.
1992;
152
1490-1500
MissingFormLabel
- 33 Nicholls W W, Avolioa A P, Kelly R P. Effects of age and of hypertension on wave travel and reflections. London: Edward Arnold In: O’Rourke MF, Safa M, dzau VJ, eds. Arterial vasodilation: mechanisms and therapy 1993: 23-40
MissingFormLabel
- 34
Nurnberger J, Opazo Saez A, Dammer S, Mitchell A, Wenzel R R, Philipp T, Schafers R F.
Left ventricular ejection time: a potential determinant of pulse wave velocity in
young, healthy males.
J Hypertens.
2003;
21
2125-2132
MissingFormLabel
- 35
Robert L.
Aging of the vascular-wall and atherosclerosis.
Exp Gerontol.
1999;
34
491-501
MissingFormLabel
- 36
Rutan G H, Kuller L H, Neaton J D, Wentworth D N, McDonald R H, Smith W M.
Mortality associated with diastolic hypertension and isolated systolic hypertension
among men screened for the Multiple Risk Factor Intervention Trial.
Circulation.
1988;
77
504-514
MissingFormLabel
- 37
Seals D R. et al .
Blood pressure reductions with exercise and sodium restriction in postmenopausal women
with elevated systolic pressure: role of arterial stiffness.
J Am Coll Cardiol.
2001;
38
506-513
MissingFormLabel
- 38
Staessen J A, Fagard R. et al .
Randomised double-blind comparison of placebo and active treatment for older patients
with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur)
Trial Investigators.
Lancet.
1997;
350
757-764
MissingFormLabel
- 39
Staessen J A. et al .
Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis
of outcome trials.
Lancet.
2000;
355
865-872
MissingFormLabel
- 40
Tavli T, Kozan O, Cin V G, Dogan A, Gokcin A.
The effects of nisoldipine on carotid artery stiffness and left ventricular functions.
Jpn Heart J.
1995;
36
629-637
MissingFormLabel
- 41
Tomiyama H. et al .
Influences of age and gender on results of noninvasive brachial-ankle pulse wave velocity
measurement - a survey of 12 517 subjects.
Atherosclerosis.
2003;
166
303-309
MissingFormLabel
- 42
Vaccarino V, Holford T R, Krumholz H M.
Pulse pressure and risk for myocardial infarction and heart failure in the elderly.
J Am Coll Cardiol.
2000;
36
130-138
MissingFormLabel
- 43
Wilking S V, Belanger A, Kannel W B, D’Agostino R B, Steel K.
Determinants of isolated systolic hypertension.
J Am Med Assoc.
1988;
260
3451-3455
MissingFormLabel
Prof. Dr. med. Markus van der Giet
Charite - Campus Benjamin Franklin, Medizinische Klinik IV - Nephrologie
Hindenburgdamm 30
12200 Berlin
Telefon: +4930/84453021
Fax: +4930/84453338
eMail: markus.vandergiet@charite.de